Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...
Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...
PITTSBURGH — A device used by diabetics is now over-the-counter, making it easier for people to get. The device could be so ...
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...
Senseonics’ Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 ...
Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients ...
Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...
Millions of UK residents have received a warning amid concerns about the underreporting of issues with a much used medical ...
Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...